👉 Background: Pfizer is the mega Pharma and biotech company that was founded back in 1849. We're talking everything from blood clot medication to pneumonia medication and, of course, the COVID vaccine.

👉 What happened: After a rocky year and major decline in sales, Pfizer is looking to push into cancer treatment for its next big break. In October last year, Pfizer acquired an oncology drug company called Seagen for $43 billion USD. And now, it's planning to release eight "blockbuster" medicines by 2030.

👉 What else: Pfizer has recently struggled to commercialise a weight loss pill as well as RSV shot. So, they are really hoping that these cancer drugs will send it back through the stratosphere.

What's the key learning?

💡In the biotech world, you're only as good as your last breakthrough drug.

💡When Pfizer released its COVID vaccine, it shot its share price through the roof. We're talking a jump of more than 118% over the first 18 months after the drug was released.

💡As the world got on top of COVID, it meant that the vaccines weren't as in-demand. And as a result, Pfizer's sales dropped 41% and its share price dropped more than 40%—or more than $100 billion USD in market value. So it's really banking on the new blockbuster drugs to keep its revenue bubbling along into the future.

‍